At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 97 enrolled
Drug / intervention
ASN002 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
In Brief
A Phase 2 clinical trial evaluating ASN002 and Placebo Oral Tablet for Chronic Hand Dermatitis. Completed, enrolled 97 participants across 23 sites in 2 countries.
Detailed Summary
Randomized double-blind/placebo study to evaluate the efficacy of ASN002 in subjects with severe chronic hand eczema.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hand Dermatitis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartJan 2019
Primary CompletionApr 2020
TodayJul 2026
First PostedNov 2, 2018
Enrollment StartJan 3, 2019
Primary CompletionApr 29, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.7 years ago
Interventions
ASN002drug
Daily dose of ASN002 for 32 weeks
Placebo Oral Tabletdrug
Daily dose of Placebo Oral Tablet for 16 weeks